Association of the BCRP C421A polymorphism with nonpapillary renal cell carcinoma

被引:41
作者
Korenaga, Y
Naito, K
Okayama, N
Hirata, H
Suehiro, Y
Hamanaka, Y
Matsuyama, H
Hinoda, Y
机构
[1] Yamaguchi Univ, Dept Urol, Sch Med, Ube, Yamaguchi 7558505, Japan
[2] Yamaguchi Univ, Dept Clin Lab Sci, Sch Med, Ube, Yamaguchi 7558505, Japan
关键词
breast cancer resistance protein; single nucleotide polymorphism; renal cell carcinoma;
D O I
10.1002/ijc.21187
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer resistance protein (BCRP), the second member of the ATP-binding cassette membrane transporter family, has a single nucleotide polymorphism, C421A (resulting in Q141K), that is of functional importance. Our aim was to explore the relationship between this polymorphism of the BCRP gene and the risk of renal cell carcinoma (RCC) development. For a case-control study, DNA samples from 200 nonpapillary RCC patients and 200 healthy control subjects were analyzed using the TaqMan technique. The genotypic frequencies of the BCRP C421A polymorphism were compared between RCC patients and control subjects. The frequency of the C/C genotype was significantly higher in RCC patients than in control subjects (age- and gender-adjusted OR = 1.96, 95% CI 1.32-2.93). No associations were observed between the BCRP C421A polymorphism and clinicopathologic or epidemiologic factors, including age, gender, tumor grade, stage, cigarette smoking, family history of cancer and body mass index. Carriers with the C/C genotype of the BCRP C421A polymorphism are at risk of developing nonpapillary RCC. These data suggest that BCRP is a candidate RCC susceptibility gene. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:431 / 434
页数:4
相关论文
共 39 条
[1]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[2]   Genetic variation in the ATP-binding Cassette Transporter gene ABCG2 (BCRP) in a Swedish population [J].
Bäckström, G ;
Taipalensuu, J ;
Melhus, H ;
Brändström, H ;
Svensson, AC ;
Artursson, P ;
Kindmark, A .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 18 (05) :359-364
[3]  
Chernomorsky S, 1999, TERATOGEN CARCIN MUT, V19, P313, DOI 10.1002/(SICI)1520-6866(1999)19:5<313::AID-TCM1>3.0.CO
[4]  
2-G
[5]   ABC of oral bioavailability: transporters as gatekeepers in the gut [J].
Dietrich, CG ;
Geier, A ;
Elferink, RPJO .
GUT, 2003, 52 (12) :1788-1795
[6]  
Gago-Dominguez M, 2001, CANCER EPIDEM BIOMAR, V10, P1001
[7]   Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma [J].
Gallou, C ;
Longuemaux, S ;
Deloménie, C ;
Méjean, A ;
Martin, N ;
Martinet, SP ;
Palais, G ;
Bouvier, R ;
Droz, D ;
Krishnamoorthy, R ;
Junien, C ;
Béroud, C ;
Dupret, JM .
PHARMACOGENETICS, 2001, 11 (06) :521-535
[8]  
HARADA S, 1993, ALCOHOL ALCOHOLISM, V28, P11
[9]  
Hibasami H, 2000, INT J MOL MED, V6, P277
[10]  
HIGUCHI S, 1995, AM J PSYCHIAT, V152, P1219